TB-500: The Complete Guide

TB-500 is a synthetic version of the active region of thymosin beta-4 (Tβ4), a 43-amino-acid peptide naturally present in nearly all human and animal cells. Tβ4 regulates actin, a protein essential for cell structure and movement, and plays a central role in tissue repair, inflammation resolution, and angiogenesis.

Unlike BPC-157, which has strong gut-healing research, TB-500 is primarily associated with systemic musculoskeletal recovery: tendons, ligaments, muscles, and joint inflammation. In the biohacking community, TB-500 is the second most popular recovery peptide after BPC-157, often used in combination.

Cell migration: TB-500 upregulates actin polymerization, enabling fibroblasts and endothelial cells to migrate to injury sites. This is the core mechanism behind accelerated wound closure in animal models.

Angiogenesis: Promotes new blood vessel formation at damaged tissue, improving nutrient delivery and waste removal during healing. Overlap with BPC-157 here, but TB-500's actin modulation is considered the distinguishing pathway.

Anti-inflammatory: Reduces inflammatory cytokines in animal injury models and may modulate NF-κB signaling. Athletes report faster resolution of chronic tendonitis and joint swelling.

Human data gap: Like BPC-157, TB-500 lacks published human clinical trials for injury recovery. Thymosin beta-4 itself has been studied in cardiac and dermal contexts, but TB-500-specific human data is essentially anecdotal.

Loading phase: 2–2.5mg subcutaneous injection, typically twice per week (e.g., Monday/Thursday), for 4–6 weeks. Some protocols use 5mg/week total split across two doses.

Maintenance: After loading, 2–2.5mg once every 1–2 weeks for ongoing support during heavy training blocks or chronic injury management.

BPC-157 stack: Common combination is BPC-157 250–500mcg daily + TB-500 2.5mg 2×/week. BPC handles local gut/tendon signaling; TB-500 supports systemic migration and angiogenesis. Many peptide clinics prescribe this pairing.

Injection sites: Subcutaneous, abdomen or near injury site (though systemic effect is the goal). Rotate injection sites. Reconstitute lyophilized powder with bacteriostatic water per vendor instructions.

BPC-157 excels at gut lining repair, localized tendon/ligament healing, and NSAID/alcohol gastric protection. TB-500 is broader for systemic tissue migration, joint inflammation, and post-surgical recovery.

For acute tendon/ligament injury: many users start both simultaneously. For gut issues: BPC-157 alone. For chronic joint inflammation without gut involvement: TB-500 alone or with BPC-157.

Cost consideration: TB-500 is typically more expensive per cycle than BPC-157 due to higher per-dose requirements (mg vs mcg dosing).

Legal: TB-500 is not approved for human use by the FDA, EMA, or TGA. Sold as a research chemical. WADA prohibits thymosin beta-4 and related peptides for competitive athletes.

Sourcing: Contamination, incorrect labeling, and peptide degradation are real risks. Third-party COA (Certificate of Analysis) with HPLC purity testing is minimum due diligence. Avoid vendors without batch-specific testing.

Medical contraindications: Active cancer (theoretical angiogenesis promotion), pregnancy, and uncontrolled autoimmune conditions warrant avoiding unsupervised use. Consult a physician familiar with peptides if considering post-surgical use.

Side effects: Community reports include temporary fatigue, headache, and injection site irritation. Systemic side effects appear uncommon at standard doses.

r/Peptides and r/Biohackers frequently discuss TB-500 + BPC-157 stacks for chronic injuries that haven't responded to conventional rehab. Success stories cluster around tendonitis, rotator cuff issues, and post-ACL recovery (alongside physical therapy).

Skeptics note the complete absence of human trials and the cost of multi-week cycles ($200–500+). Consensus: reasonable to try after exhausting conventional options, not a first-line treatment. Physical therapy remains non-negotiable.